VERADERMICS INC. O.N.

Veradermics stock dropped intraday by up to 4.8% to $97.90 under pressure from ongoing insider sales. CEO Reid Alexander Waldman and firms linked to directors reported large disposals in the days before (including 67,500, 100,000 and 750,000 shares). At the same time, the company reported a net loss of $23.5 million in Q2 2026 (prior year $15.6 million) and announced 16.77 million additional shares for potential sale, stoking dilution fears. Analysts such as Citi and Jefferies remain positive on the VDPHL01 pipeline but could not offset the short-term selling pressure. » More on de.investing.com

Veradermics reports positive results from the open‑label Phase‑2 study 207 of VDPHL01, an oral minoxidil formulation for the treatment of female hair loss. 88.9% (once daily) and 90.0% (twice daily) of participants reported improved or much improved outcomes after six months; the mean increase in non‑vellus hairs was about 22.7–23.3 hairs/cm². VDPHL01 showed no safety‑relevant signal through month six, and Veradermics expects topline results from the Phase‑2/3 study 306 in H1 2027 and from the Phase‑3 study 304 for male hair loss in H2 2026. » More on de.investing.com

Veradermics will hold an investor call with webcast on Wednesday at 8:00 a.m. ET to present the results from the female treatment arms of phase 2 study 207 of VDPHL01. VDPHL01 is an orally administered, non‑hormonal minoxidil tablet with extended‑release formulation that is already in phase 3 development. The company emphasizes that the formulation avoids high peak concentrations and prolongs the duration of effect above the defined minimum growth threshold; patent protection extends until 2043. » More on de.investing.com